Jun Gong: Dual publication in JCO Precision Oncology
Jun Gong, Medical Oncologist and Researcher in Gastrointestinal and Genitourinary cancers at Cedars-Sinai, shared on X:
“Dual publication in JCO Precision Oncology.
1) NCI-MATCH Subprotocol K2 positive PhII trial: activity of Erdafitinib in treatment-refractory tumors with FGFR1-3 mutations or fusions, adding to evidence for potential tumor agnostic indication?
2) NCI-MATCH Subprotocol K1 PhII trial: no activity (0% ORR) of Erdafitinib in tumors with FGFR1-4 amplifications, informative that not all FGFR alterations may be targetable.”
Source: Jun Gong/X
About OncoDaily
OncoDaily was founded in 2023. It is a US-based oncology media platform, which features the latest news, insights, and patient stories from the world of oncology. Within a short period of time it became one of the leading oncology media platforms globally.
OncoDaily gathers content from various sources, including social media posts from renowned oncologists from all over the world, news from oncology societies and cancer centers, patient and survivor stories, and career-related information for professionals.
The mission of OncoDaily is to empower patients, survivors, and professionals with the knowledge and inspiration they need to fight cancer. The motto of OncoDaily is “Cancer doesn’t take a day off – neither do we.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023